The assay at the heart of the study targets methylation changes in five genes: SEPTIN9, BCAT1, IKZF1, BCAN and VAV3. DNA methylation is an epigenetic modification in which methyl groups are added to cytosine bases, typically at CpG dinucleotides, altering gene expression without changing the underlying genetic code. Cancer cells acquire highly characteristic methylation patterns, including widespread silencing of tumor-suppressor genes through promoter hypermethylation. Because these patterns are stable, reproducible and often tissue- or tumor-specific, methylated DNA fragments released into the bloodstream by dying tumor cells serve as a molecular fingerprint of malignancy. Circulating cell-free DNA, or cfDNA, carries these marks, and polymerase chain reaction-based assays can be designed to detect them even when tumor-derived fragments represent only a tiny fraction of the total cfDNA pool, which is otherwise dominated by DNA from blood cells.

SEPTIN9 is the most familiar name on the list, having already underpinned a commercially available plasma test for colorectal cancer screening in several countries. BCAT1, IKZF1, BCAN and VAV3 add complementary signals, and the logic of a multi-gene panel is straightforward: no single methylation marker is shed by every tumor, so combining several independent targets increases the chance that at least one will be detectable in a given patient. The five-gene assay evaluated here converts methylation measurements across these targets into a single composite result, classified as positive or negative, which was then benchmarked against pathology, the gold standard that definitively establishes whether a patient has cancer after tissue examination.

The study population came from a single colorectal surgery department, a design choice with important implications for how the results should be read. All 412 patients had plasma cfDNA methylation testing and routine serum tumor-marker evaluation performed either before surgery or before starting treatment, and each case was adjudicated by pathology. The final analysis compared 219 patients with confirmed colorectal cancer against 193 patients whose diagnoses were not colorectal cancer, a mix that reflects the genuine clinical question a hospital faces: distinguishing malignant from non-malignant disease among symptomatic patients referred to a surgical service. This is a harder and more realistic test than comparing cancer patients against healthy volunteers, because the control group includes people with polyps, inflammatory conditions and other colorectal pathologies that can confound biomarker performance.

The headline numbers tell a consistent story. The methylation assay achieved a sensitivity of 73.5 percent, meaning it correctly flagged roughly three out of four cancers, with a 95 percent confidence interval running from 67.7 to 79.4 percent. Its specificity of 91.2 percent, with a confidence interval of 87.2 to 95.2 percent, indicates that false positives were relatively uncommon. The area under the receiver operating characteristic curve, a summary of overall discriminatory ability that ranges from 0.5 for a useless test to 1.0 for a perfect one, reached 0.873. CEA, by contrast, detected only 35.9 percent of cancers, though its specificity was higher at 96.7 percent, yielding an AUC of 0.730. The difference in AUC between the two tests was statistically significant, with a p-value below 0.001 on the DeLong test, a standard method for comparing correlated receiver operating characteristic curves.

The researchers also explored whether combining the two markers would help. An either-positive rule, in which a patient is considered positive if either the methylation assay or CEA is positive, pushed sensitivity up to 79.9 percent but dragged specificity down to 88.6 percent, producing an AUC of 0.843. That trade-off illustrates a fundamental principle of diagnostic test design: combining tests with independent signals raises the chance of catching true cases but simultaneously accumulates false positives from each component. For a test intended as an adjunctive risk-stratification tool rather than a standalone diagnosis, the modest gain in sensitivity may or may not justify the additional false positives, a calculation that depends on the clinical setting, the cost of follow-up colonoscopy and the prevalence of disease in the tested population.

Perhaps the most biologically revealing results concern how performance scaled with tumor burden. Sensitivity climbed from 56.8 percent in stage I disease to 100 percent in stage IV, from 38.1 percent in T1 tumors to 94.1 percent in T4 tumors, and from 53.6 percent in tumors measuring two centimeters or less to 95.0 percent in tumors larger than six centimeters. This gradient is exactly what the biology of circulating tumor DNA predicts. Early tumors are small, have limited cell turnover and relatively poor blood supply at their margins, so they shed comparatively little DNA into circulation. Advanced tumors, with larger mass, greater necrosis and more active remodeling of the tumor microenvironment, release far more methylated DNA fragments, making them easier to detect. The pattern is a double-edged sword: it confirms the assay is genuinely measuring tumor-derived material, but it also means the test is weakest precisely where a screening tool would deliver the greatest benefit, at the earliest and most curable stages.

This stage dependence is not a flaw unique to this assay; it is an inherent constraint of liquid biopsy technology that the field has grappled with since its inception. Detecting a handful of tumor DNA fragments among the vast background of healthy cfDNA is an analytical challenge comparable to finding a needle in a haystack, and the needle count rises with tumor size and stage. Strategies to improve early detection include deeper sequencing, larger panels of methylation targets, optimized DNA extraction and amplification chemistry, and multimodal algorithms that integrate methylation with other features such as fragmentomics and mutation profiling. The authors of the current study are careful to frame their five-gene assay as a complement to existing modalities, including colonoscopy and established screening programs, rather than a replacement for them.

The real-world design of the study is both its greatest strength and its principal limitation. By testing the assay in a consecutive clinical cohort from a single surgical department, the researchers captured performance under the messier conditions of actual practice, where patient characteristics, sample handling and comorbidities deviate from the idealized settings of model-development studies. Yet the single-center, single-department, retrospective nature of the work means the findings cannot be generalized wholesale. A cohort drawn from a colorectal surgery clinic overrepresents symptomatic patients and advanced disease, so sensitivity in an asymptomatic screening population would likely be lower than the figures reported here. Specificity, too, depends on the composition of the control group, and a healthier population might shift the numbers in either direction. The authors themselves emphasize that large-scale, multi-center prospective studies are needed to define the assay’s utility across diverse screening and diagnostic settings before it can be recommended for broad clinical deployment.

Even with those caveats, the study adds meaningful weight to the case for methylation-based liquid biopsy in colorectal cancer, a disease that remains one of the most common and deadly malignancies worldwide despite being highly curable when caught early. A blood test that reliably outperforms CEA, a marker that has been in clinical use for decades yet misses nearly two-thirds of cancers in this cohort, represents a tangible step toward less invasive and more accessible detection pathways. The five-gene panel’s 0.873 AUC in a real-world surgical cohort, achieved with a technically simple PCR-based workflow on routine plasma samples, suggests that epigenetic blood testing is maturing from promising concept to clinically credible instrument. The road ahead runs through prospective validation in screening populations, standardization of laboratory protocols and careful health-economic analysis, but the direction of travel is now unmistakable: the chemical marks that tumors stamp on their DNA are becoming a readable, quantifiable and increasingly trustworthy signal in modern cancer medicine.

Subject of Research: Diagnostic performance of a five-gene plasma cell-free DNA methylation assay for colorectal cancer detection compared with CEA

Article Title: Performance of a five-gene plasma cfDNA methylation assay for colorectal cancer detection: a single-center real-world analysis

Article References: Chen, B., Xu, X., Yuan, H., Wan, Z., Du, W., Yu, Q., Qian, Y., Wang, J., Yu, Y., Lyu, J., Yang, Z., & Zheng, B. (2026). Performance of a five-gene plasma cfDNA methylation assay for colorectal cancer detection: a single-center real-world analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17047-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17047-2

Keywords: colorectal cancer, cfDNA methylation, liquid biopsy, SEPTIN9, CEA, early detection, epigenetics, tumor biomarkers, real-world study, BMC Cancer, diagnostic sensitivity, circulating tumor DNA